MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijid.2025.108252

Медицинская библиотека · International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025

Cancer and COVID-19: A review of immune insights and partnerships to inform public health strategy.

Hempel Heidi, Xue Huijing, La Shu Shin, Jain Shweta, Kemp Troy J, Pinto Ligia A

СтатьяОбзорПеревод пока не подготовлен

Аннотация

OBJECTIVE

To summarize current evidence on SARS-CoV-2 vaccine immunogenicity in cancer populations, review the experimental approaches and assays used to evaluate multilayer immunity, and highlight emerging collaborative efforts that support more standardized and comprehensive immune profiling.

METHODS

We reviewed published clinical and immunological studies assessing vaccine-induced humoral, cellular, and mucosal immunity in hematologic and solid cancer populations, with attention to experimental approaches, assay standardization, and factors contributing to variability in immune readouts.

RESULTS

Cancer populations are highly vulnerable to respiratory viral infections (RVIs) due to disease- and treatment-related immunosuppression. SARS-CoV-2 is a particularly severe threat in this population and COVID-19 is associated with higher rates of hospitalization and mortality compared to immunocompetent individuals. Vaccination remains the most effective preventive method. However, immune responses to vaccination in cancer patients are often heterogeneous and weaker than in healthy populations. While booster doses can improve the protection, vaccine effectiveness wanes over time, and some patients may not respond well, with significant variability across cancer types, cancer status and treatment regimens. These observations highlight the importance of more personalized vaccination strategies informed by a thorough understanding of immune correlates of protection, including humoral, cellular, and mucosal immunity. Assessing different layers of immunity requires different experimental approaches, robust assay standardization and data harmonization. The collaborative efforts of consortia and the development of large, well-annotated biospecimen repositories can support high-resolution immune profiling, advance next-generation vaccine strategies and improve sustained protection against SARS-CoV-2 and other respiratory viruses in cancer populations.

CONCLUSIONS

Cancer populations show heterogeneous and often weaker vaccine-induced immunity, highlighting the need for more personalized vaccination strategies. Improving sustained protection requires a deeper understanding of multilayer immune responses and the use of robust, standardized assays that allow reliable comparisons across studies and patient groups.

Для цитирования: Hempel Heidi, Xue Huijing, La Shu Shin, Jain Shweta, Kemp Troy J, Pinto Ligia A. Cancer and COVID-19: A review of immune insights and partnerships to inform public health strategy.. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2025. DOI: 10.1016/j.ijid.2025.108252.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.